IGF-1 LR3 vs CJC-1295 + Ipamorelin: Which Has Better Muscle-Growth Evidence?

Quick answer: IGF-1 LR3 vs CJC-1295 + Ipamorelin for muscle growth is really a choice between two different evidence types, not two competing "winners." IGF-1 LR3 has the more direct anabolic-signalling mechanism, backed mostly by cell and animal data. CJC-1295 + Ipamorelin has more human data, but it measures GH release, not muscle mass. Neither has a controlled human hypertrophy trial - see our full muscle-growth evidence guide for how every compound in this space is graded.

Search interest that pairs IGF-1 LR3 with CJC-1295 and Ipamorelin has grown alongside the broader best peptides for muscle growth research conversation - researchers comparing the two main mechanistic routes to muscle-growth signalling: supplying the anabolic signal directly, or raising the hormones that produce it upstream. This guide compares IGF-1 LR3 with CJC-1295 + Ipamorelin mechanism by mechanism, grades the human evidence for each using New-U's muscle-growth peptide research evidence scale, and is honest about where both leave off. Research use only; nothing here is dosing guidance or a human-use recommendation.

How to read this comparison. IGF-1 LR3 and CJC-1295 + Ipamorelin are not interchangeable options for the same question - they represent two different research strategies on the same GH/IGF-1 axis. We compare mechanism, evidence type, and evidence grade, not "which works better," because no controlled human trial answers that for either.

What Is IGF-1 LR3?

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analogue of IGF-1, the downstream mediator of many of growth hormone's anabolic effects. The LR3 modification reduces binding to IGF-binding proteins and extends the active half-life well beyond native IGF-1. In cell and animal models it drives satellite-cell activation, myoblast proliferation and protein synthesis - the core biological signals behind muscle hypertrophy. Full profile: IGF-1 LR3 research guide; analogue detail: IGF-1 DES vs IGF-1 LR3.

What Is CJC-1295 + Ipamorelin?

CJC-1295 is a modified GHRH(1-29) analogue acting on the pituitary's GHRH receptor. Ipamorelin is a selective pentapeptide acting on the ghrelin/GHS-R1a receptor. They act on different receptors with non-overlapping mechanisms, and pre-clinical work shows the combination evoking a larger GH pulse than either alone - the standard reason the pair is studied together rather than separately. Full mechanism detail: CJC-1295 & Ipamorelin research guide.

IGF-1 LR3 vs CJC-1295 + Ipamorelin: Mechanism Compared

Compound Mechanism Receptor Position on the GH/IGF-1 axis IGF-1 LR3 Direct IGF-1 receptor signalling IGF-1 receptor Downstream (the anabolic signal itself) CJC-1295 GHRH analogue Pituitary GHRH receptor Upstream (raises endogenous GH) Ipamorelin Selective ghrelin mimetic GHS-R1a (ghrelin receptor) Upstream (raises endogenous GH, different receptor to CJC-1295)

IGF-1 LR3 skips the upstream hormone cascade entirely and supplies IGF-1 receptor stimulation directly. CJC-1295 + Ipamorelin instead raises the body's own GH pulse, which then raises endogenous IGF-1 - an indirect route with an extra regulatory step (and an extra opportunity for the body's own feedback loops to intervene).

Human Evidence Compared

Graded on New-U's muscle-growth evidence scale (A = controlled human hypertrophy data, down to E = cell/mechanistic evidence only):

Compound Evidence Grade What the grade means here IGF-1 LR3 D Animal-model signalling data; no controlled human trial of the LR3 analogue CJC-1295 + Ipamorelin C Human GH-pulse pharmacodynamic data; no controlled human hypertrophy trial of the pairing

CJC-1295 + Ipamorelin sits one grade above IGF-1 LR3 on this scale - but that reflects human hormonal measurement, not a human muscle-growth outcome. Both compounds are missing the same thing: a controlled trial that measures muscle tissue itself in humans.

Does IGF-1 LR3 Build Muscle?

Not according to any controlled human trial. IGF-1 LR3's evidence base is cell-culture and animal-model work showing satellite-cell activation and protein-synthesis signalling - real biology, but not a demonstrated human outcome. IGF-1 signalling is also a cell-proliferation pathway, which is part of why it is studied carefully rather than casually.

Does CJC-1295 + Ipamorelin Build Muscle?

Not according to any controlled human trial either. What is published is human data on GH-pulse amplitude when the two peptides are studied together - evidence that the combination changes hormone release, not evidence that it changes muscle mass. The GH/IGF-1 axis is the mechanism under study, not a proven muscle-building pathway.

Which Should Researchers Study First?

That depends on the research question, not on which compound is "stronger." A study interested in direct IGF-1 receptor signalling and satellite-cell biology has more reason to reference IGF-1 LR3. A study interested in GH-axis pharmacodynamics, receptor selectivity, or GHRH/GHRP synergy has more reason to reference CJC-1295 + Ipamorelin. Neither answers a muscle-hypertrophy question on its own, and this page is not a recommendation to use either compound outside a laboratory research setting. For how the two are sometimes discussed as complementary rather than competing mechanisms, see Best Peptide Stack for Muscle Growth: What the Research Shows.

Frequently Asked Questions

Is IGF-1 LR3 better than CJC-1295 + Ipamorelin for muscle growth? Neither has controlled human hypertrophy evidence, so "better" cannot be answered as a proven outcome. IGF-1 LR3 has the more direct anabolic-signalling mechanism; CJC-1295 + Ipamorelin has more human pharmacodynamic (GH-release) data. Which is "better" depends entirely on the research question being asked.

Can IGF-1 LR3 and CJC-1295 + Ipamorelin be studied together? Mechanistically they are non-redundant - IGF-1 LR3 acts downstream at the IGF-1 receptor while CJC-1295 + Ipamorelin acts upstream on GH release - which is why research literature sometimes discusses them in the same GH/IGF-1 axis context. This is a description of research framing, not a usage recommendation.

Which has stronger human evidence? CJC-1295 + Ipamorelin has more human data, but it is pharmacodynamic (hormone-release) evidence, not hypertrophy evidence. IGF-1 LR3's evidence base is almost entirely cell and animal-model signalling data. Neither compound has a controlled human muscle-growth trial.

Are IGF-1 LR3 and CJC-1295 + Ipamorelin WADA-prohibited? Yes. IGF-1 and its analogues fall under WADA's S2 category (peptide hormones, growth factors and mimetics), and GH secretagogues including CJC-1295 and Ipamorelin are prohibited under the same category. Any tested athlete should treat both research groups as off-limits in competition.

Buy Ipamorelin from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research